Skip to main content

Table 1 Cyberknife® publications for primary treatment of prostate cancer

From: Long-term intra-fractional motion of the prostate using hydrogel spacer during Cyberknife® treatment for prostate cancer – a case report

Author Dose scheme No. of patients Median follow-up (moths) FFBF (in % by risk group) Early toxicity in % Late toxicity in % Patients receiving ADT in %
low (l) intermediate (i) high (h) GU GI GU GI
G1 G2 G3 G1 G2 G3 G3 G3  
Friedland et al. 2009[5] 7 and 7.25 Gy × 5 112 24   l,i,h: 97.3         0 1 19
Bolzicco et al. 2010[17] 7 Gy × 5 45 20 l,i:100   36 11 0 24 24 0 22 0 38
Freeman et al. 2011[18] 7 and 7.25 Gy × 5 41 60 92.7       *    25 0 0
Kang et al. 2011[19] 8,8.5, and 9 Gy × 4 44 40 100 100 90.8 n.A. 14 0 n.A. 9 0 0 0 87
King et al. 2012[20] 7.25 Gy × 5 67 32 94 (4-year)          3 0 0
McBride et al. 2012[21] 7.25 and 7.25 Gy × 5 45 44 97.7 (3-year)    59 19 0 31 7 0 2 5 0
Oliai et al. 2012[2] 7,7.25 and 7.5 Gy × 5 70 31 100 94.7 77.1 56 19 4 17 4 0 3 0 33
Katz et al. 2013[4] 7 and 7.25 Gy × 5 304 60 97.7 (3-year) 90.7 74.1 72-75 4-5 0 75-76 4 0 2 0 19
Chen et al. 2013[3] 7 and 7.25 Gy × 5 100 28 100 100 88 36 35 0 35 5 0 0 <1 11
King 2013[6], pooled date 7-7.25 Gy × 5 1100 36 95 83 78          14
  1. *Acute symptoms typically resolved within one month of treatment completation.
  2. FFBF: freedom from biochemical failure, GU: genitourinary, GI: gastrointestinal, G: Grade, ADT: androgen deprivation therapy.